Tripos Discovery Research, CombinatoRx Pen Drug-Development Deal | GenomeWeb
NEW YORK (GenomeWeb News) — Tripos Discovery Research today said it will use its computational and medicinal chemistry and ADME services to “optimize” certain “synergistic” pharmaceutical combinations discovered by CombinatoRx.
Tripos is a wholly owned subsidiary of Commonwealth Biotechnologies.
Financial terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.